SX682
Oral Squamous Cell Carcinoma
National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Oral Squamous Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cetuximab National Cancer Institute (NCI) | Phase 1/2 | B |
Irinotecan AIDS Malignancy Consortium | Phase 1/2 | B |
Carboplatin Rapa Therapeutics LLC | Phase 1/2 | B |
Nivolumab National Cancer Institute (NCI) | Phase 2 | CCC |
Abiraterone Acetate MacroGenics | Phase 2 | CCC |
View all 22 →
Same molecule, other indications
SX682 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →